Ibiglustat

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

一种口服活性、选择性和有效的葡萄糖神经酰胺合酶 (GCS) 抑制剂，可进入中枢神经系统 (CNS)。

An orally active, selective and potent Glucosylceramide synthase (GCS) inhibitor with central nervous system (CNS) access; exhibits significantly lower tissue levels of GL-3 and lyso-GL-3 and a delayed progression of a thermal nociceptive response in administered Fabry mice; shows favorable pharmacological properties and safety profile.Other Indication Phase 2 Clinical(In Vitro):Ibiglustat (SAR402671) (1 μM, 15 days; Fabry disease (FD) cells) is close to the physiological level in untreated WT cells in GL-3 levels, suggesting that Ibiglustat can prevent additional GL-3 accumulation and could serve to ameliorate the abundant levels of this sphingolipid in FD cardiomyocytes.

——

——

Venglustat | Genz-682452 | GZ452

Others

Other Targets

glucosylceramide synthase

Other Indications

Other Disease

1401090-53-6

389.49

C20H24FN3O2S

>98% (HPLC)

DMSO: 10 mM （ < 1 mg/ml refers to the product slightly soluble or insoluble )

O=C(O[C@@H]1CN2CCC1CC2)NC(C)(C3=CSC(C4=CC=C(F)C=C4)=N3)C

(3S)-1-azabicyclo[2.2.2]octan-3-yl N-{2-[2-(4-fluorophenyl)- 1,3-thiazol-4-yl]propan-2-yl}carbamate

(-20℃)

With Ice Pack

≥ 2 years